Noriaki Takeda, Go Sato, Kazunori Matsuda, Juichi Ito, Koichi Omori, Yatsuji Ito, Tadashi Kitahara, Izumi Koizuka, Hideo Shojaku, Mamoru Suzuki, Katsumi Doi, Toshihisa Murofushi, Hiroshi Yamashita
OBJECTIVE: In the present study, we examined the effects of high-dose betahistine on dizziness handicap inventory (DHI) scores in patients with unilateral vestibulopathy. METHODS: An uncontrolled, open-label, multicenter clinical trial was conducted. Fifteen patients with unilateral vestibulopathy, such as vestibular neuritis, who complained of intractable dizziness for more than three months were enrolled. Initially, all patients were orally administered betahistine at a dose of 36 mg/day for four weeks, which is the standard dose and dosing period for the treatment of dizziness in Japan...
September 2, 2023: Auris, Nasus, Larynx